ARWR: I looked a bit at their website and heard a couple calls. The obesity drug is sub-q which I think would be a big obstacle. On one of the calls they talked about possibly dosing it less often (but it was like every other day not good enough IMO). The presenter also mentioned about formulating it as a monthly injection now that would be a viable solution if can achieve comparable efficacy and not increase side effects. If they get anywhere near the mice data (I think the primate data wasn't bad either) could see it with more potential.
I agree with your earlier comments about financing being a big risk. I think their burn is ~1 million a month. They also implied they weren't near getting the type of collaborations that could prevent them from having to do financings. So I gather they are pretty early stage. I didn't look to see how many options/warrants they have seems they through in some warrants with each financing so maybe stock isn't a cheap as it looks?
Market Data 
Markets 
AI
